Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for sarcopenia.

Journal of cachexia, sarcopenia and muscle - 1 Aug 2024

Yin Kang-Fu, Chen Ting, Gu Xiao-Jing, Su Wei-Ming, Jiang Zheng, Lu Si-Jia, Cao Bei, Chi Li-Yi, Gao Xia, Chen Yong-Ping

Abstract excerpt

BACKGROUND: There are no effective pharmacological treatments for sarcopenia. We aim to identify potential therapeutic targets for sarcopenia by integrating various publicly available datasets. METHODS: We integrated druggable genome data, cis-eQTL/cis-pQTL from human blood and skeletal muscle tissue, and GWAS summary data of sarcopenia-related traits to analyse the potential causal relationships between drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bayes Theorem
Share to AURKA gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Associations and Epidemiology

Share to Genome-Wide Association Study

Share to Mendelian Randomization Analysis

Share to Nutrition and Health in Aging

Share to Polymorphism, Single Nucleotide

Share to Sarcopenia

Source

Open in PubMed Open full text

Identifiers

PMID: 38644354
DOI: 10.1002/jcsm.13479
PMCID: PMC11294052

Genes

COL15A1
HP
MFGE8
AURKA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for sarcopenia.PMID 38644354Read ↗

Association Analysis of the Circulating Proteome With Sarcopenia‐Related Traits Reveals Potential Drug Targets for SarcopeniaSemantic proximity Read ↗

Sarcopenia and chronic pain: Identification of shared genetic determinants and therapeutic implication.Semantic proximity Read ↗

Identifying genetic determinants of sarcopenia-related traits: a Mendelian randomization study of druggable genes.Semantic proximity Read ↗

Sarcopenia and immune-mediated inflammatory diseases: Evaluating causality and exploring therapeutic targets for sarcopenia through Mendelian randomization.Semantic proximity Read ↗

Metabolome-Wide Mendelian Randomization Assessing the Causal Relationship Between Blood Metabolites and Sarcopenia-Related Traits.Semantic proximity Read ↗

Putative Candidate Drug Targets for Sarcopenia-Related Traits Identified Through Mendelian Randomization Analysis of the Blood ProteomeSemantic proximity Read ↗

Dissecting Immune Mechanisms Underlying Sarcopenia Using Multi-omics Approaches.Semantic proximity Read ↗

Mapping the genetically predicted associations of plasma metabolites with sarcopenia and aging traits: Evidence from bidirectional Mendelian randomization and transcriptome analysis.Semantic proximity Read ↗

Mitochondria-Related Genome-Wide Mendelian Randomization Identifies Putatively Genes for Chronic Fatigue.Semantic proximity Read ↗

TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitroSemantic proximity Read ↗

Mendelian randomization and colocalization analysis reveal novel drug targets for myasthenia gravis.Semantic proximity Read ↗

Causal Relationship Between Circulating Metabolites and Sarcopenia‐Related Traits: A Mendelian Randomization and Experimental StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.